

09/848,986.

FILE 'HOME' ENTERED AT 12:02:44 ON 08 MAR 2004

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 12:03:15 ON 08 MAR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 12:03:15 ON 08 MAR 2004

FILE 'CAPLUS' ENTERED AT 12:03:15 ON 08 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:03:15 ON 08 MAR 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 12:03:15 ON 08 MAR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s DNA (4a) PK  
L1 2141 DNA (4A) PK

=> s l1 and immunomodulatory  
L2 15 L1 AND IMMUNOMODULATORY

=> s l2 and Ku antigen  
L3 2 L2 AND KU ANTIGEN

=> d l3 bib abs 1-2

L3 ANSWER 1 OF 2 USPATFULL on STN  
AN 2003:251584 USPATFULL  
TI Agents that modulate **DNA-PK** activity and methods of  
use thereof  
IN Raz, Eyal, Del Mar, CA, UNITED STATES  
Lois, Augusto, Escondido, CA, UNITED STATES  
Takabayashi, Kenji, San Diego, CA, UNITED STATES  
PI US 2003176373 A1 20030918  
AI US 2001-848986 A1 20010504 (9)  
PRAI US 2000-202274P 20000505 (60)  
US 2001-262321P 20010117 (60)  
DT Utility  
FS APPLICATION  
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO  
PARK, CA, 94025  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 14 Drawing Page(s)  
LN.CNT 2162  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides methods for modulating cell death in a  
eukaryotic cell, and methods for reducing DNA damage in a eukaryotic  
cell. The methods generally comprise modulating a biological activity of  
**DNA-PK** in a cell. The invention further provides  
methods of treating a condition related to cell death in an individual.

09567863

The invention further provides methods of identifying agents which modulate a biological activity of **DNA-PK**, as well as agents identified by the methods. Methods of modulating an immune response using an identified agent are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 2 USPATFULL on STN  
AN 2003:181451 USPATFULL  
TI Agents that modulate **DNA-PK** activity and methods of use thereof  
IN Raz, Eyal, Del Mar, CA, UNITED STATES  
Lois, Augusto, S. Escondido, CA, UNITED STATES  
Takabayashi, Kenji, San Diego, CA, UNITED STATES  
PI US 2003125284 A1 20030703  
AI US 2002-233121 A1 20020830 (10)  
RLI Division of Ser. No. US 2001-848986, filed on 4 May 2001, PENDING  
PRAI US 2000-202274P 20000505 (60)  
US 2001-262321P 20010117 (60)  
DT Utility  
FS APPLICATION  
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 2077

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for modulating cell death in a eukaryotic cell, and methods for reducing DNA damage in a eukaryotic cell. The methods generally comprise modulating a biological activity of **DNA-PK** in a cell. The invention further provides methods of treating a condition related to cell death in an individual. The invention further provides methods of identifying agents which modulate a biological activity of **DNA-PK**, as well as agents identified by the methods. Methods of modulating an immune response using an identified agent are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:02:44 ON 08 MAR 2004)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:03:15 ON 08 MAR 2004

L1 2141 S DNA (4A) PK  
L2 15 S L1 AND IMMUNOMODULATORY  
L3 2 S L2 AND KU ANTIGEN

=> s l1 and ku (4a) antigen

L4 73 L1 AND KU (4A) ANTIGEN

=> s l4 ans purine

MISSING OPERATOR L4 ANS

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l4 and purine

L5 3 L4 AND PURINE

09567863

=> s l5 not l3

L6 1 L5 NOT L3

=> d l6 bib abs

L6 ANSWER 1 OF 1 USPATFULL on STN

AN 2003:220740 USPATFULL

TI Methods and compositions for diagnosing and treating rheumatoid arthritis

IN Pittman, Debra D., Windham, NH, UNITED STATES  
Feldman, Jeffrey L., Arlington, MA, UNITED STATES  
Shields, Kathleen M., Harvard, MA, UNITED STATES  
Trepicchio, William L., Andover, MA, UNITED STATES

PI US 2003154032 A1 20030814

AI US 2001-23451 A1 20011217 (10)

PRAI US 2000-255861P 20001215 (60)

DT Utility

FS APPLICATION

LREP Patent Group, FOLEY, HOAG & ELIOT LLP, One Post Office Square, Boxton, MA, 02109

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 25385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

09567863

=> d his

(FILE 'HOME' ENTERED AT 12:02:44 ON 08 MAR 2004)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:03:15 ON  
08 MAR 2004

L1 2141 S DNA (4A) PK  
L2 15 S L1 AND IMMUNOMODULATORY  
L3 2 S L2 AND KU ANTIGEN  
L4 73 S L1 AND KU (4A) ANTIGEN  
L5 3 S L4 AND PURINE  
L6 1 S L5 NOT L3

=> s l4 and pkc

L7 1 L4 AND PKC

=> d l7 bib abs

L7 ANSWER 1 OF 1 USPATFULL on STN  
AN 2003:276724 USPATFULL  
TI Wortmannin derivatives as probes of cellular proteins and processes  
IN Wandless, Thomas J., Menlo Park, CA, UNITED STATES  
Cimprich, Karlene, Menlo Park, CA, UNITED STATES  
Chu, Gilbert, Palo Alto, CA, UNITED STATES  
Stohlmeyer, Michelle, Chicago, IL, UNITED STATES  
Fas, Cornelia, Schwaebisch Gmuend, GERMANY, FEDERAL REPUBLIC OF  
PI US 2003194749 A1 20031016  
AI US 2003-368248 A1 20030218 (10)  
PRAI US 2002-357538P 20020215 (60)  
DT Utility  
FS APPLICATION  
LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 3204  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB One aspect of the present invention relates to methods and reagents for  
profiling cells and/or subcellular environments (e.g., membrane or  
nuclear cellular fractions). The invention uses small molecule probes  
that bind covalently to protein targets, which significantly simplifies  
purification and identification of proteins using full length or  
proteolyzed proteins. Proteins, cellular components or other binding  
partners (collectively known as "LBP" or "lipid binding partner") can be  
naturally occurring, such as proteins or fragments of proteins cloned or  
otherwise derived from cells, or can be artificial, e.g., polypeptides  
which are selected from random or semi-random polypeptide libraries.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

09567863

=> s l1 and purine?  
L8 82 L1 AND PURINE?

=> s l8 and activity  
L9 81 L8 AND ACTIVITY

=> s l9 and modulat?  
L10 63 L9 AND MODULAT?

=> s l10 and py<=2000  
2 FILES SEARCHED...  
4 FILES SEARCHED...  
L11 3 L10 AND PY<=2000

=> dup rem l11  
PROCESSING COMPLETED FOR L11  
L12 3 DUP REM L11 (0 DUPLICATES REMOVED)

=> d l12 bib abs 1-3

L12 ANSWER 1 OF 3 USPATFULL on STN  
AN 2001:190916 USPATFULL  
TI Method for detecting qualitative and quantitative alterations in DNA and  
ligands of said alteration ligands  
IN Chaubron, Franck, Chamalieres, France  
Provot, Christian, Le Cendre, France  
PA Genolife, France (non-U.S. corporation)  
PI US 6309838 B1 20011030  
WO 9853099 19981126 <--  
AI US 1999-424120 19991119 (9)  
WO 1998-FR1008 19980520  
19991119 PCT 371 date  
19991119 PCT 102(e) date  
PRAI FR 1997-6102 19970520  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Myers, Carla J.; Assistant Examiner: Forman, B J  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1220  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention concerns a method for detecting impairment of DNA  
comprising contacting a sample DNA with a composition comprising at  
least one recognition protein selected from the group consisting of  
proteins belonging to the nucleotide excision repair system, proteins  
belonging to the base excision repair system, and proteins belonging to  
the system for detecting DNA breaks and detecting a complex formed  
between the recognition protein and DNA to thereby detect impairment of  
the DNA sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 3 USPATFULL on STN  
AN 2000:97994 USPATFULL  
TI Human protein kinase and kinase inhibitors  
IN Lal, Preeti, Santa Clara, CA, United States  
Hillman, Jennifer L., Mountain View, CA, United States  
Bandman, Olga, Mountain View, CA, United States  
Corley, Neil C., Mountain View, CA, United States

09567863

Shah, Purvi, Sunnyvale, CA, United States  
PA Incyte Genomics, Inc., Palo Alto, CA, United States (U.S. corporation)  
PI US 6096308 20000801 <--  
AI US 1999-231529 19990114 (9)  
RLI Division of Ser. No. US 1997-977816, filed on 25 Nov 1997  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Saidha, Tekchand  
LREP Incyte Genomics, Inc.  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 25 Drawing Page(s)  
LN.CNT 2897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human protein kinase (PK) and kinase inhibitors (PKI) and polynucleotides which identify and encode PK and PKI. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of PK and PKI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 3 USPATFULL on STN  
AN 2000:4947 USPATFULL  
TI MDM2-specific antisense oligonucleotides  
IN Chen, Jiandong, Metairie, LA, United States  
Agrawal, Sudhir, Shrewsbury, MA, United States  
Zhang, Ruiwen, Marietta, GA, United States  
PA Hybridon, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 6013786 20000111 <--  
AI US 1998-73567 19980506 (9)  
RLI Continuation-in-part of Ser. No. US 1997-916384, filed on 22 Aug 1997  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Wang, Andrew  
LREP McDonnell Boehnen Hulbert & Berghoff  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN 18 Drawing Figure(s); 21 Drawing Page(s)  
LN.CNT 1809

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.